Tags : Novel E3 Ligases

Roche Signs an Exclusive Worldwide Option and License Agreement with

Shots: Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up […]Read More